RICHMOND HILL, ONTARIO- Helix BioPharma Corp. (TSX: HBP), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that it will be presenting at the RHK Capital 2019 Disruptive Growth & Healthcare Conference (www.disruptnyc.com).
RHK Capital’s Disruptive Growth & Healthcare Conference showcases life science companies that focus on solutions for unmet medical needs and growth companies with disruptive technologies and business models. The 2019 Disruptive Growth & Healthcare Conference will be held on Wednesday, September 4th and Thursday, September 5th in New York.